This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Novartis' (NVS) NSCLC Drug Fails to Meet Primary Endpoint
by Zacks Equity Research
Novartis (NVS) pipeline candidate, canakinumab, fails to meet the primary endpoint in lung cancer study.
BioMarin (BMRN) Hemophilia Gene Therapy Gets FDA's RMAT Tag
by Zacks Equity Research
FDA grants RMAT designation to BioMarin's (BMRN) gene therapy for severe hemophilia A, valoctocogene roxaparvovec, after rejecting it last year.
Pfizer's (PFE) Vaccine Seems Potent Against COVID-19 Strains
by Zacks Equity Research
Pfizer's (PFE) coronavirus vaccine seems to neutralize the more contagious variants of the original coronavirus in laboratory studies.
Pfizer/Valneva Lyme Disease Vaccine Candidate Enters Phase II
by Zacks Equity Research
Pfizer (PFE) and Valneva are jointly developing a vaccine candidate for Lyme disease. It is the only candidate in clinical development.
Pfizer (PFE) Stock Moves -0.55%: What You Should Know
by Zacks Equity Research
Pfizer (PFE) closed the most recent trading day at $34.20, moving -0.55% from the previous trading session.
Pfizer (PFE) Down 1.3% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Pfizer (PFE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Pfizer's (PFE) Lorbrena Gets FDA Nod for First-Line Lung Cancer
by Zacks Equity Research
Pfizer's (PFE) label expansion application for Lorbrena as first-line treatment for metastatic lung cancer gets approval in the United States.
Merck (MRK) to Help J&J Make COVID-19 Vaccine to Boost Supply
by Zacks Equity Research
Merck (MRK) will use its existing facilities to manufacture and supply J&J's newly approved COVID-19 vaccine.
The Zacks Analyst Blog Highlights: Johnson & Johnson, Pfizer, BioNTech, Moderna and AstraZeneca
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Johnson & Johnson, Pfizer, BioNTech, Moderna and AstraZeneca
Aerie (AERI) Rises Despite Q4 Earnings Miss, Revenues Top Mark
by Zacks Equity Research
Aerie (AERI) up more than 16% despite reporting a wider-than-expected loss in the fourth quarter of 2020. Revenues beat estimates.
FDA Emergency Nod for J&J COVID-19 Vaccine Heats Up Competition
by Kinjel Shah
J&J's (JNJ) single shot COVID-19 vaccine gets FDA emergency use authorization. U.S. CDC Advisory Committee also recommends J&J's vaccine.
Pharma Stock Roundup: SNY/GSK & PFE COVID-19 Vaccine Update, MRK's Pandion Buyout
by Kinjel Shah
Sanofi (SNY) & Glaxo (GSK) start phase II study on their COVID-19 vaccine candidate. Merck (MRK) offers to buy Pandion Therapeutics for $1.85 billion
Ionis (IONS) Q4 Earnings Decline Y/Y, Sales Beat Estimates
by Zacks Equity Research
Ionis (IONS) Q4 adjusted earnings decline year over year. The company issues guidance for 2021.
Corcept (CORT) Q4 Earnings In Line, Revenues Miss Estimates
by Zacks Equity Research
Corcept's (CORT) earnings meet estimates in the fourth quarter of 2020 while revenues miss the same.
The Zacks Analyst Blog Highlights: Pfizer, BioNTech, Moderna and Johnson & Johnson
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Pfizer, BioNTech, Moderna and Johnson & Johnson
Viatris (VTRS) Declines on Lackluster Outlook, Announces Dividend
by Zacks Equity Research
Viatris (VTRS) declines after it announces outlook for 2021 and reaffirms strategic commitments.
What's in the Cards for BioNTech (BNTX) This Earnings Season?
by Zacks Equity Research
On BioNTech's (BNTX) fourth-quarter earnings call, investors are likely to focus on sales number for its COVID-19 vaccine, BNT162b2, which has been developed in partnership with Pfizer.
FDA Issues New Guidelines for COVID-19 Vaccines, Tests, Drugs
by Kinjel Shah
The FDA encourages companies to evaluate the impact of COVID-19 virus variants on the efficacy or performance of their COVID-19 vaccines, tests and medicines.
Coronavirus Vaccine Sales Key to Moderna's (MRNA) Q4 Earnings
by Zacks Equity Research
Investors are likely to focus on Moderna's (MRNA) sales guidance for its coronavirus vaccine in 2021 on the fourth-quarter earrings call.
Pfizer (PFE), BioNTech Test COVID-19 Vaccine in Pregnant Women
by Zacks Equity Research
Pfizer (PFE) and BioNTech begin dosing in a mid-to-late-stage study on their COVID-19 vaccine in healthy pregnant women.
Pharma Stock Roundup: Coronavirus Vaccine Updates From PFE, AZN & JNJ
by Kinjel Shah
WHO authorizes emergency use of AstraZeneca's (AZN) COVID-19 vaccine. J&J (JNJ) seeks conditional approval for its COVID-19 vaccine in EU.
Pfizer/BioNTech to Sell More COVID-19 Vaccine Doses to EU
by Zacks Equity Research
Pfizer (PFE)/BioNTech (BNTX) win a deal for 200 million more doses of its COVID-19 vaccine in Europe.
J&J (JNJ) Seeks Conditional Nod for COVID-19 Vaccine in EU
by Zacks Equity Research
J&J's (JNJ) COVID-19 vaccine, if approved, will be the only COVID-19 vaccine to be approved for single administration.
Pfizer (PFE) Gets FDA Nod for New Indication of Immunoglobulin
by Zacks Equity Research
Pfizer's (PFE) Panzyga gets FDA approval to treat chronic inflammatory demyelinating polyneuropathy (CIDP), a rare neurological disease.
AbbVie (ABBV) Inks CAR T Deal, Gets Botox Label Expansion Nod
by Zacks Equity Research
AbbVie (ABBV) signs an agreement to research and develop two new CAR-T cell therapies. The FDA approves label expansion of Botox for pediatric patients.